The news is directly about Ultragenyx Pharmaceutical. The maintained Overweight rating indicates that Piper Sandler still sees the stock as a good investment, but the lowered price target may indicate a slightly less optimistic outlook. This could have a neutral impact on the stock's price in the short term.